Parkside Financial Bank & Trust’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $158K | Buy |
1,041
+33
| +3% | +$5.01K | 0.02% | 494 |
|
|
2025
Q1 | $152K | Buy |
1,008
+93
| +10% | +$14K | 0.02% | 449 |
|
|
2024
Q4 | $169K | Sell |
915
-95
| -9% | -$17.5K | 0.02% | 421 |
|
|
2024
Q3 | $199K | Buy |
1,010
+26
| +3% | +$5.12K | 0.03% | 367 |
|
|
2024
Q2 | $203K | Sell |
984
-59
| -6% | -$12.2K | 0.03% | 344 |
|
|
2024
Q1 | $283K | Buy |
1,043
+164
| +19% | +$44.4K | 0.05% | 283 |
|
|
2023
Q4 | $208K | Buy |
879
+118
| +16% | +$27.9K | 0.04% | 298 |
|
|
2023
Q3 | $149K | Buy |
761
+74
| +11% | +$14.5K | 0.03% | 316 |
|
|
2023
Q2 | $144K | Sell |
687
-45
| -6% | -$9.46K | 0.03% | 319 |
|
|
2023
Q1 | $148K | Buy |
732
+96
| +15% | +$19.4K | 0.04% | 293 |
|
|
2022
Q4 | $139K | Buy |
636
+38
| +6% | +$8.28K | 0.04% | 299 |
|
|
2022
Q3 | $118K | Buy |
598
+144
| +32% | +$28.4K | 0.04% | 302 |
|
|
2022
Q2 | $98K | Sell |
454
-15
| -3% | -$3.24K | 0.03% | 350 |
|
|
2022
Q1 | $133K | Buy |
469
+80
| +21% | +$22.7K | 0.04% | 291 |
|
|
2021
Q4 | $147K | Sell |
389
-24
| -6% | -$9.07K | 0.04% | 284 |
|
|
2021
Q3 | $171K | Buy |
413
+11
| +3% | +$4.55K | 0.05% | 225 |
|
|
2021
Q2 | $149K | Buy |
402
+25
| +7% | +$9.27K | 0.04% | 250 |
|
|
2021
Q1 | $109K | Buy |
+377
| New | +$109K | 0.03% | 301 |
|